← Back to headlines
Roivant shares soar after inhaled lung disease drug succeeds in mid-stage trial
Roivant Sciences said its experimental inhaled drug met goals in a mid-stage trial for a lung disease, sending shares up 17%.
8 Sept, 10:57 — 8 Sept, 16:36
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (37/100)3 sources25/33
Spectrum spread— 2/5 buckets covered8/33
Far L
Left
Center1
Center (1)
investing-com
Right2
Right (2)
Barron'sseeking-alpha
Far R
Geographic diversity— 1 region4/34
US3
ℹAll sources from US region
Sources
Showing 2 of 3 sources
Barron'sHigh2h ago
Roivant Sciences Stock Soars as Experimental Inhaled Drug Hits Mid-Stage Trial Goals - Barron's
Roivant Sciences Stock Soars as Experimental Inhaled Drug Hits Mid-Stage Trial Goals Barron's
Read full article →seeking-alphaMixed8h ago
Roivant climbs on mid-stage trial win for lung disease candidate
Read full article →Coverage Timeline
First report: seeking-alpha · 8 Sept, 10:57|Full coverage: 3 · 6h|Window: 6h
Left-leaningCenterRight-leaning
